Sep 06, 2023 / 05:00PM GMT
Yigal Nochomovitz - Citigroup - Analyst
Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. As long as I can remember, we always do a targeted oncology panel at our conference. So, this is the 2023 version of that panel. We have two terrific companies from IDEAYA, Paul Stone, CFO; from ORIC, Matt Panuwat, am I saying that correctly?
Matt Panuwat - ORIC Pharmaceuticals - Chief Business Officer
That's correct. Yeah.
Yigal Nochomovitz - Citigroup - Analyst
Okay. Great. The Chief Business Officer; and from Syndax, Mike Metzger, the CEO. Thank you all so much for taking time out of the one-on-one scheduled to chat a little bit. Maybe we can just go down the line and just do a quick two to three minute high-level overview of what the company does, what are the key assets, maybe the key studies, and then we can get into a discussion about design considerations for targeted oncology drugs. So, you want to kick it off, Matt?
Matt Panuwat - ORIC Pharmaceuticals - Chief
IDEAYA Biosciences Inc at Citi Global Technology Conference Transcript
Sep 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers